Antisynthetase Syndrome

1. Disease Information

Overview. Antisynthetase syndrome (ASSD / ASyS / ASS) is a systemic autoimmune disease, a distinct subset of the idiopathic inflammatory myopathies (IIM), defined serologically by circulating autoantibodies directed against one of the cytoplasmic aminoacyl-tRNA synthetases (aaRS). It is clinically dominated by a triad of interstitial lung disease (ILD), inflammatory myositis, and inflammatory (usually non-erosive) arthritis, frequently accompanied by the "ancillary" features mechanic's hands, Raynaud phenomenon, and unexplained fever. ILD is the chief driver of morbidity and mortality and often predominates at presentation, so the disorder is genuinely a multisystem connective-tissue disease rather than "just a myopathy."

"Antisynthetase syndrome is characterized by symptoms of muscle weakness, arthritis, mechanic's hands, interstitial lung disease (ILD), Raynaud phenomenon, and a positive anti–tRNA-synthetase antibody." [search-derived]

Key identifiers: - MONDO: MONDO:0019344 — antisynthetase syndrome [verified via local OAK] - Orphanet: ORPHA:81 (Antisynthetase syndrome) - OMIM: No single Mendelian OMIM entry (complex/polygenic autoimmune disease — not a monogenic disorder) - ICD-10: No dedicated code; typically captured under M35.8 (other specified systemic involvement of connective tissue) or the myositis/ILD codes (e.g., M33.x dermatomyositis/polymyositis; J84.x for the ILD component) - ICD-11: 4A41 region (overlap/undifferentiated connective tissue diseases / inflammatory myopathies); no unique stem code - MeSH: No standalone MeSH descriptor; indexed via "Myositis," "Lung Diseases, Interstitial," and the supplementary concept for aminoacyl-tRNA synthetase autoantibodies

Data derivation: Disease-level aggregated resources (review syntheses, multicenter cohorts such as AENEAS, registry/population studies). A small amount is EHR/population-based (e.g., the Olmsted County population cohort, PMID 39814448).

Synonyms / alternative names: Anti-synthetase syndrome; anti-aminoacyl-tRNA synthetase syndrome; anti-ARS syndrome; ASyS; ASSD; Jo-1 syndrome (when anti-Jo-1 positive — a partial synonym); "antisynthetase syndrome–associated ILD (ASS-ILD)" for the pulmonary-predominant phenotype.

2. Etiology

Causal factors. ASSD is a multifactorial autoimmune disease — there is no single causal gene or pathogen. It arises from a loss of immune tolerance to one or more aaRS enzymes in a genetically susceptible host, likely triggered or amplified by environmental/mucosal (especially pulmonary) exposures. The serological hallmark — an anti-aaRS antibody whose titer tracks disease activity — implies the autoantibody response is mechanistically central rather than a bystander.

"titers of the serum anti-Jo-1 antibodies correlate with disease activity" — Kanaji et al., Trends Biochem Sci (PMID 36280495) [verified]

Genetic risk factors (susceptibility loci — not Mendelian causes): - MHC class II is the strongest risk locus. In Caucasian patients, HLA-DRB1*03:01 and the linked HLA-B*08:01, HLA-DQA1*05:01, and HLA-DQB1*02:01 alleles (the ancestral 8.1 haplotype) are the principal predisposing markers, particularly for anti-Jo-1. HLA-DRB1*07:01 appears protective. [search-derived] - In Korean/Japanese populations, anti-ARS associates with HLA-DRB1*08:03 (an example of population-specific HLA risk). [search-derived] - Non-HLA candidate: single-nucleotide variants in IL1B influencing IL-1β serum levels have been reported as susceptibility factors (PMC7732678). [search-derived]

Environmental / lifestyle risk factors: - Sex: female predominance (≈2–3:1 female:male). - Smoking: associated with increased risk of anti-Jo-1 positivity specifically in HLA-DRB1*03–positive individuals — a candidate gene–environment interaction. - Age: peak onset in the 5th–6th decades.

Gene–environment interaction (mechanistic hypothesis): the interaction between HLA-DRB1*03 and cigarette smoke is hypothesized to promote anti-Jo-1 generation — analogous to the smoking × shared-epitope model in rheumatoid arthritis, with the lung as the site of tolerance breakdown (post-translational modification/neoantigen exposure of HisRS in inflamed lung). [search-derived]

Protective factors: HLA-DRB1*07:01 (genetic, above). No well-established environmental protective factor.

3. Phenotypes

ASSD presents as "complete" (full triad) or, more commonly, "incomplete" forms; manifestations accrue over time, so the picture evolves. Approximate frequencies vary widely by cohort and by antibody (see §9). The figures below are pooled from the diagnosis/treatment review (PMID 27594777) [verified] and standard reviews.

Phenotype characteristics: Adult-onset (mean 43–60 yr; see §9). Onset is subacute-to-chronic and insidious; course is typically chronic, relapsing, and frequently progressive in the lung. Severity is highly variable — from clinically amyopathic/ILD-only (often non-Jo-1 antibodies) to fulminant myositis or rapidly progressive ILD. Mechanic's hands and Raynaud are markers of the syndrome but rarely disabling; ILD severity drives prognosis.

Quality-of-life impact: Dominated by the ILD (exertional dyspnea, oxygen dependence, reduced exercise capacity) and by myositis-related functional limitation (climbing, lifting, swallowing). Arthritis adds RA-like functional impairment. No ASSD-specific PRO instrument; SF-36/EQ-5D and myositis tools (e.g., HAQ, Myositis Activities Profile) are used generically.

4. Genetic / Molecular Information

This is not a Mendelian disease — there are no causal germline mutations. The "molecular genetics" are HLA susceptibility (see §2): HLA-DRB1*03:01, HLA-B*08:01, DQA1*05:01, DQB1*02:01 (8.1 haplotype) confer risk; DRB1*07:01 protective; DRB1*08:03 in East Asians. HGNC anchors for the relevant loci: HGNC:4948 HLA-DRB1, HGNC:4932 HLA-B, HGNC:4942 HLA-DQA1, HGNC:4944 HLA-DQB1; HGNC:5992 IL1B (candidate modifier).

Autoantigen genes (the targets of the autoantibodies, not mutated genes): the eight aaRS genes — HGNC:4815 HARS1 (HisRS / Jo-1), HGNC:11572 TARS1 (ThrRS / PL-7), HGNC:348 AARS1 (AlaRS / PL-12), HGNC:6053 IARS1 (IleRS / OJ), HGNC:4162 GARS1 (GlyRS / EJ), HGNC:751 NARS1 (AsnRS / KS), HGNC:3650 FARSB (PheRS / Zo), HGNC:6512 KARS1 (LysRS / SC/Ha).

No somatic variants, no chromosomal abnormalities, no established disease-specific epigenetic signature define ASSD. The molecular pathology is autoantibody- and immune-mediated, not genomic. Functional consequence of the autoimmunity is loss-of-tolerance and immune-complex formation (see §6), not loss/gain of aaRS enzymatic function.

Modifier serologies (act like molecular modifiers of phenotype): anti-Ro52/TRIM21 co-positivity (up to ~50% of patients) associates with more ILD and worse pulmonary outcome. HGNC:11312 TRIM21.

5. Environmental Information

• Smoking — strongest candidate environmental factor; interacts with HLA-DRB1*03 to promote anti-Jo-1 (see §2). [search-derived]
• Pulmonary exposures / mucosal injury — the lung is hypothesized as the initiating site where aaRS (HisRS) is secreted/modified and presented, breaking tolerance (consistent with ILD-predominant presentations). [verified mechanism, PMID 36280495]
• Infectious agents: No specific pathogen is established as causal. Viral infection is a proposed nonspecific "danger signal" that upregulates aaRS secretion from infected macrophages (secretome studies show aaRS release from virus-infected macrophages, PMID 36280495 [verified]), but ASSD is not an infectious disease.
• Occupational/toxin exposures: none specifically established.

6. Mechanism / Pathophysiology

The current model is a self-amplifying innate-plus-adaptive autoimmune loop centered on aaRS autoantigens, with the lung and muscle as the principal sites. Cited details are from Kanaji et al. (PMID 36280495) [verified] unless noted.

Causal chain (upstream → downstream):

1. Tissue injury / regeneration + tissue-specific aaRS secretion (upstream trigger). Damaged or regenerating muscle (and inflamed lung) upregulate MHC class I on myofibers and secrete certain aaRSs. IGF-1–stimulated human skeletal muscle cells selectively secrete HisRS (not MetRS), and most ASSD-linked aaRSs appear in the secretome/exosomes of differentiating myoblasts and virus-infected macrophages — implicating extracellular mobility as a key determinant of which aaRS becomes an autoantigen (~85% of patients target a class IIa aaRS not bound in the multisynthetase complex).

   "most aaRSs detected from the secretome/exosome of human differentiating myoblasts and virus-infected primary macrophages are associated with ASSD."

2. Neoepitope exposure — the WHEP domain. HisRS (Jo-1) is the dominant target (30–60%). The immunodominant epitope is the WHEP domain — a small (~50-aa) helix-turn-helix motif outside the catalytic core that is "highly exposed and flexible, often disordered." A lung-enriched HisRS splice variant (aa 1–60) and a granzyme-B cleavage fragment (HisRS1-48) expose this domain extracellularly, linking cytotoxic muscle/lung injury to autoantigen generation.

3. Antigen presentation & T-cell help. Dendritic cells take up secreted aaRS and present peptides on MHC class II (HLA-DR) to aaRS-specific CD4+ T cells, driving B-cell help and class-switched autoantibody production.

4. Immune-complex formation + TLR-driven interferon (the amplification loop). Anti-Jo-1 binds HisRS together with HisRS-bound tRNA/tRNA fragments, forming immune complexes. Via Fcγ receptors, complexes are internalized into endosomes where the nucleic-acid cargo triggers TLR7/8, releasing type I interferon and proinflammatory cytokines — a positive feedback loop that perpetuates autoantibody production. A 5′-half tRNA-His fragment released in extracellular vesicles can activate endosomal TLR7.

   "the HisRS/tRNA complex is internalized to the endosome, where the tRNA triggers TLR7/8 signaling and interferon release."

5. Interferon programs (effector arm). ASSD muscle shows type II IFN–inducible genes (e.g., PSMB8) and MHC-II/HLA-DR upregulation on myofibers; type I IFN drives autoantibody persistence and MHC class I overexpression. In ASS-ILD, monocyte-driven IFN and TNF programs orchestrate the inflammatory network (Frontiers Immunol 2025, PMC12589074). [search-derived]

6. Neutrophils / NETs (tissue-damage effector). Myositis-specific antibodies promote NET formation with impaired NET degradation, contributing to injury in lung, muscle, and vessels — a proposed driver of the fibrotic ILD (parallels RA-ILD NET biology). [search-derived]

7. Chemokine activity of the autoantigen. The HisRS WHEP domain has intrinsic chemokine-like activity (activates chemokine receptors on T cells and immature dendritic cells), recruiting immune cells to tissues expressing/secreting it — a built-in feed-forward to sites like muscle and lung.

8. Downstream tissue damage → clinical disease. The net result is interstitial lung inflammation/fibrosis, myofiber injury (perimysial/perifascicular, with MHC-I upregulation), synovitis, and vasculopathy (Raynaud, mechanic's hands).

Ontology suggestions: - GO (biological processes): GO:0002377 immunoglobulin production; GO:0019882 antigen processing and presentation; GO:0002224 toll-like receptor signaling pathway; GO:0032606 type I interferon production; GO:0032609 type II interferon production / GO:0034341 response to type II interferon; GO:0006954 inflammatory response; GO:0140447 cytokine production involved in inflammatory response; (NET formation: GO:0140148-family — verify a current NETosis GO ID); GO:0004812 aminoacyl-tRNA ligase activity (autoantigen's native function). - CL (cell types): CL:0000576 monocyte; CL:0000775 neutrophil; CL:0000451 dendritic cell; CL:0000624 CD4-positive T cell; CL:0000236 B cell; CL:0000786 plasma cell; CL:0002063 type II pneumocyte; CL:0000057 fibroblast; CL:0000187 muscle cell / CL:0000188 skeletal muscle cell. - GO cellular component (subcellular): GO:0005768 endosome (TLR signaling site); GO:0005737 cytoplasm (aaRS native compartment).

7. Anatomical Structures Affected

Organ level (primary): - Lung (UBERON:0002048) — interstitium; ILD is the dominant organ injury. Patterns: NSIP (most common), organizing pneumonia, UIP, sometimes diffuse alveolar damage. - Skeletal muscle (UBERON:0001134; muscle organ UBERON:0002385) — inflammatory myopathy, perimysial/perifascicular distribution. - Joints / synovium (UBERON:0002217 synovial joint; UBERON:0002484 synovial membrane) — inflammatory arthritis.

Secondary / additional involvement: - Skin (UBERON:0002097) — mechanic's hands; sometimes DM-like rash (Gottron, heliotrope) in overlap. - Peripheral vasculature / digital vessels — Raynaud phenomenon. - Esophagus (UBERON:0001043) — dysphagia from striated-muscle involvement. - Heart (UBERON:0000948) — under-recognized myocarditis and pulmonary hypertension/right-heart strain (late). [search-derived: anti-Jo-1 myocarditis reports]

Body systems: respiratory, musculoskeletal, integumentary, cardiovascular, immune.

Tissue/cell level: alveolar epithelium (type II pneumocytes), pulmonary interstitial fibroblasts/myofibroblasts; skeletal myofibers; synovial lining; recruited monocytes, neutrophils, T and B cells.

Localization / lateralization: ILD is bilateral, typically basal/peripheral predominant. Myositis is proximal and symmetric. Arthritis is symmetric/polyarticular. Mechanic's hands are bilateral on radial/ulnar finger surfaces.

8. Temporal Development

• Onset: Adult, mean age 43–60 yr (range ~19–82); peak incidence 50–59 yr. Pattern is subacute-to-chronic/insidious; a minority present with rapidly progressive ILD (acute, potentially fatal).
• Progression: Manifestations accumulate over time ("incomplete" → "complete" syndrome). The AENEAS time-course work shows new features (e.g., ILD, arthritis) emerging during follow-up. ILD course ranges from stable to relentlessly progressive fibrosis; ~32–35% progress despite steroids + immunosuppressant, requiring rescue therapy. [search-derived]
• Disease course pattern: Chronic, relapsing-remitting to progressive; lifelong. Muscle and joint disease often respond to immunosuppression; ILD is the limiting factor.
• Remission: Treatment-induced remission of myositis/arthritis is common; ILD often only stabilizes. Spontaneous remission is uncommon.
• Critical windows: Early aggressive treatment of rapidly progressive ILD is the key intervention window; delayed diagnosis (common, due to under-recognition and incomplete presentations) worsens outcome.

9. Inheritance and Population

Epidemiology: - Incidence: age-/sex-adjusted ~0.56 per 100,000/year (95% CI 0.25–0.87) in a US population-based cohort (Olmsted County, 1998–2019; PMID 39814448). [search-derived] - Prevalence: rare; not precisely established. Orphanet lists it as a rare disease. - Sex ratio: female-predominant, ~2–3:1 (some myositis-predominant cohorts skew more female). - Age distribution: adult, peak 5th–6th decade.

Inheritance: Not inherited in a Mendelian fashion — multifactorial/polygenic with HLA-driven susceptibility. No penetrance/expressivity/anticipation/mosaicism/carrier-frequency concepts apply. Founder/population effects appear only at the level of population-specific HLA risk alleles (DRB1*03:01 in Europeans; DRB1*08:03 in East Asians). Consanguinity is not relevant.

Antibody distribution (defines serologic subgroups): - Anti-Jo-1 (HARS1): most common — ~20–30% of all IIM; ~70–88% of antisynthetase patients (72% in AENEAS, n=828). Phenotype: classic triad, more myositis. - Anti-PL-7 (TARS1): ~18% of anti-ARS (Japanese cohort). - Anti-PL-12 (AARS1): ~11%; ILD-predominant, often amyopathic, less muscle. - Anti-EJ (GARS1): ~23% (Japanese); myositis-associated. - Anti-OJ (IARS1): ~5%; ILD-predominant. - Anti-KS (NARS1): ~8%; ILD-predominant, minimal myositis. - Anti-Zo (FARSB) and anti-Ha/SC (KARS1): rare.

"Myositis was closely associated with anti-Jo-1, anti-EJ, and anti-PL-7, while interstitial lung disease (ILD) was correlated with all 6 anti-ARS antibodies." [search-derived]

Co-antibody: anti-Ro52/TRIM21 in up to ~50% — marks more severe ILD.

Geographic distribution: Worldwide; no strong endemicity. Subtype distribution shifts by ancestry (e.g., higher anti-EJ in Japanese cohorts).

10. Diagnostics

Diagnosis = anti-aaRS antibody + ≥1 compatible clinical feature (per Connors); Solomon criteria are stricter. Connors/Lega criteria are more sensitive; specificities are comparable. [verified PMID 27594777 + search-derived]

Serology (cornerstone): - Myositis line/immunoblot panels detecting the 8 anti-aaRS (anti-Jo-1, PL-7, PL-12, EJ, OJ, KS, Zo, Ha). Immunoprecipitation remains a reference method (best for anti-OJ, which line blots miss). Anti-Ro52 should be tested concurrently. - Caveat: patients can be antibody-positive yet "seronegative" by limited panels (anti-OJ, anti-KS frequently missed) — clinical suspicion matters.

Laboratory: - Creatine kinase (LOINC:2157-6) and aldolase — elevated with active myositis (may be normal in amyopathic/ILD-predominant disease). - ANA (often negative or low-titer cytoplasmic pattern — a clue), aldolase, LDH, AST/ALT.

Imaging: - HRCT chest — NSIP/OP/UIP patterns; the key ILD test. - Muscle MRI — edema/inflammation, guides biopsy.

Functional / electrophysiology: - Pulmonary function tests (PFTs) with DLCO — restrictive pattern, reduced diffusion; monitored every 2–3 months until remission. - EMG — irritable myopathy.

Biopsy / pathology: - Muscle biopsy — characteristic perimysial fragmentation, perifascicular necrosis, MHC-I sarcolemmal upregulation (distinct from DM's perifascicular atrophy and PM's endomysial pattern). - Lung biopsy — rarely needed; cellular/fibrotic NSIP, OP.

Genetic testing: Not used diagnostically (no Mendelian basis). HLA typing is research/risk-stratification only. WGS/WES/panels/karyotype/CMA/FISH/mtDNA/repeat testing are not applicable.

Omics-based diagnostics: Investigational — peripheral-blood IFN signatures, monocyte transcriptomics (ASS-ILD), and autoantibody profiling are research tools, not validated clinical diagnostics.

Clinical criteria: Connors (2010), Solomon (2011), Lega; ACR/EULAR IIM criteria capture the myositis component but not ILD-predominant ASSD.

Differential diagnosis: Other IIM (DM, PM, IMNM, IBM); idiopathic pulmonary fibrosis / idiopathic NSIP; rheumatoid arthritis (ASSD arthritis is RA-mimicking, can be anti-CCP–negative → "seronegative RA" reclassified as ASSD); systemic sclerosis/MCTD; hypersensitivity pneumonitis; Sjögren-ILD.

Screening: No population screening. In a patient with unexplained ILD, myositis antibody panel is the key targeted "screen."

11. Outcome / Prognosis

• Mortality / survival: 10-year cumulative survival ~70% (anti-Jo-1) vs ~49% (non-Jo-1); one 5-year cohort (n=45) showed 14% mortality; AENEAS-era and registry cohorts report overall mortality ~25%. [verified PMID 27594777 + search-derived]
• Leading causes of death: progressive pulmonary fibrosis and pulmonary hypertension; rapidly progressive ILD acutely.
• Prognostic factors: Better — anti-Jo-1 positivity, presence of arthritis, presence of muscle weakness; Worse — severe baseline dyspnea, absent muscle weakness (ILD-only phenotype), non-Jo-1 antibodies, anti-Ro52 co-positivity, UIP-pattern fibrosis, PAH, older age.
• Anti-Jo-1 antibody level tracks disease activity/evolution and is being evaluated as a longitudinal biomarker (PMC11137886, PMC10362709). [search-derived]
• Malignancy: Cancer risk in ASSD is lower than in classic dermatomyositis but the population cohort (PMID 39814448) examined malignancy association — verify the specific hazard before citing.
• Morbidity/QoL: chronic dyspnea, oxygen dependence, exercise limitation, myositis-related functional loss, RA-like joint disability.

12. Treatment

No randomized controlled trials exist — management is consensus/expert-based. (MAXO:0000058-family immunosuppressive therapy; NCIT:C15986 Pharmacotherapy as the action term.)

First line: - Glucocorticoids (prednisone/prednisolone), medium-to-high dose — CHEBI:8382 prednisone / CHEBI:8378 prednisolone; agent class NCIT:C2322 Corticosteroid. (MAXO:0000058? prefer NCIT:C15986 + corticosteroid agent.) - Steroid-sparing immunosuppressant added early — mycophenolate mofetil (CHEBI:8764), azathioprine (CHEBI:2948), or tacrolimus (CHEBI:61049) as add-on.

"prednisone AND mycophenolate mofetil or azathioprine; consider tacrolimus as add-on therapy" — PMID 27594777 [verified]

Refractory / progressive ILD: - Rituximab (anti-CD20 mAb; rescue therapy; PFT improvement at ~6 months) — agent NCIT:C2480 Rituximab; modality MONOCLONAL_ANTIBODY. - Cyclophosphamide (CHEBI:4026) for severe/rapidly progressive ILD or ARDS-like presentation. - IVIG — adjunct, especially for refractory myositis/dysphagia. - Combination MMF + rituximab reported beneficial in refractory IIM. [search-derived]

Antifibrotic (emerging): Nintedanib (CHEBI:85164) for progressive fibrosing ILD phenotypes (extrapolated from INBUILD/progressive-pulmonary-fibrosis data) — investigational/adjunct in ASS-ILD.

Targeted/experimental: JAK inhibitors (targeting the IFN axis) and other biologics are under study; numerous trials for myositis-ILD on ClinicalTrials.gov (search for active NCTs before listing).

Supportive / rehabilitative: supplemental oxygen, pulmonary rehabilitation, physical/occupational therapy (MAXO:0000011 physical therapy), aspiration precautions for dysphagia, vaccination/PJP prophylaxis under immunosuppression, lung transplantation for end-stage ILD (MAXO:0010039 organ transplantation).

Pharmacogenomics: TPMT/NUDT15 genotyping before azathioprine (myelosuppression risk) — standard CPIC guidance; the one genotype-guided step relevant to ASSD therapy.

Monitoring: PFTs/DLCO every 2–3 months until remission; CK and muscle strength for myositis; HRCT for ILD progression.

13. Prevention

• Primary prevention: None established (autoimmune, multifactorial). Smoking cessation is the only modifiable lifestyle lever plausibly reducing risk (given the smoking × HLA-DRB1*03 interaction).
• Secondary prevention (early detection): Early myositis-antibody testing in unexplained ILD/arthritis, and HRCT/PFT screening in newly diagnosed antibody-positive patients, to catch ILD before irreversible fibrosis. No population screening program.
• Tertiary prevention: Immunosuppression to prevent ILD progression; infection prophylaxis (PJP, vaccination) while immunosuppressed; PAH surveillance; aspiration precautions.
• Immunization, genetic screening/counseling, public-health/environmental interventions: Not applicable as disease-specific measures (no infectious or Mendelian basis); standard immunosuppression-related vaccination applies.

14. Other Species / Natural Disease

• Taxonomy: Human disease — NCBITaxon:9606 (Homo sapiens).
• Natural disease in other species: None recognized. ASSD has no described naturally occurring animal counterpart (no OMIA entry). It is defined by human anti-aaRS autoantibodies in a specific HLA context.
• Orthologous autoantigen genes (for comparative/model work): the aaRS genes are deeply conserved (essential housekeeping enzymes) across all species — e.g., mouse Hars1 (NCBI Gene mouse ortholog), etc. — but conservation of the enzyme does not imply conservation of the disease.
• Zoonotic potential / cross-species transmission: None (non-infectious autoimmune disease).

15. Model Organisms

ASSD is difficult to model; no single model recapitulates the full human triad.

• Mouse immunization models: Immunization with HisRS / Jo-1 (and especially the WHEP/N-terminal fragment) in adjuvant induces muscle and lung inflammation (myositis + ILD-like pulmonary infiltrates) in mice — the principal experimental system supporting the autoantigen-driven model (referenced in PMID 36280495 mechanism work). Evidence source: MODEL_ORGANISM.
• In vitro / cellular: Human skeletal myoblast and macrophage secretome/exosome studies (HisRS secretion on IGF-1 stimulation; aaRS release from virus-infected macrophages); TLR7/8 reporter assays with tRNA fragments; T-cell activation assays of the HisRS WHEP domain (chemokine activity / NRP2 binding). Evidence source: IN_VITRO. (PMID 36280495 [verified].)
• Genetic models: No knockout/knock-in disease model (aaRS knockouts are embryonic-lethal — these are essential enzymes), so reverse-genetic disease modeling is intrinsically limited.
• Recapitulation & limitations: Immunization models reproduce muscle + lung autoimmunity and the autoantibody response, supporting the antigen-specific hypothesis, but do not reproduce the chronic fibrotic ILD, arthritis, mechanic's hands, or the human HLA context — a clear HUMAN_MODEL_MISMATCH candidate for a knowledge-gap note (model autoimmunity ≠ human chronic fibrosing multisystem disease).
• Applications: mechanism of tolerance breakdown, role of aaRS fragments/WHEP domain, TLR/IFN amplification loop, candidate-therapy testing.

Consolidated Ontology Term Suggestions (for YAML)

• Disease: MONDO:0019344 antisynthetase syndrome.
• HPO phenotypes: HP:0006530 (ILD), HP:0003701 (proximal weakness), HP:0003198 (myopathy), HP:0001369 (arthritis), HP:0002829 (arthralgia), HP:0010765 (palmar hyperkeratosis ≈ mechanic's hands — verify), Raynaud (verify term), HP:0001945 (fever), HP:0002094 (dyspnea), HP:0003236 (elevated CK), HP:0002015 (dysphagia), HP:0002206 (pulmonary fibrosis), HP:0002092 (PAH).
• GO: GO:0002377, GO:0019882, GO:0002224, GO:0032606, GO:0034341, GO:0006954, GO:0004812.
• CL: CL:0000576, CL:0000775, CL:0000451, CL:0000624, CL:0000236, CL:0000786, CL:0002063, CL:0000057, CL:0000188.
• UBERON: UBERON:0002048 (lung), UBERON:0001134 (skeletal muscle tissue), UBERON:0002217 (synovial joint), UBERON:0002097 (skin), UBERON:0001043 (esophagus).
• CHEBI (drugs): CHEBI:8382 prednisone, CHEBI:8764 mycophenolate mofetil, CHEBI:2948 azathioprine, CHEBI:61049 tacrolimus, CHEBI:4026 cyclophosphamide, CHEBI:85164 nintedanib.
• MAXO/NCIT (treatments): NCIT:C15986 Pharmacotherapy (+ agents); MAXO:0000011 physical therapy; MAXO:0010039 organ transplantation; MAXO:0000950 supportive care.

Key References (PMIDs to fetch & verify before curation)

Sources (URLs): - https://pmc.ncbi.nlm.nih.gov/articles/PMC9974581/ (mechanism review, PMID 36280495) - https://pmc.ncbi.nlm.nih.gov/articles/PMC5006392/ (diagnosis/treatment, PMID 27594777) - https://pmc.ncbi.nlm.nih.gov/articles/PMC9136399/ (aaRS: on anti-synthetase syndrome and beyond) - https://pmc.ncbi.nlm.nih.gov/articles/PMC11050089/ (ASS-ILD review) - https://pubmed.ncbi.nlm.nih.gov/39814448/ (population epidemiology) - https://pmc.ncbi.nlm.nih.gov/articles/PMC11137886/ (anti-Jo-1 levels & prognosis) - https://pmc.ncbi.nlm.nih.gov/articles/PMC6222225/ (HLA/genetics, Hungarian cohort) - https://pmc.ncbi.nlm.nih.gov/articles/PMC7732678/ (IL1B susceptibility) - https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1652999/full (monocyte IFN/TNF in ASS-ILD) - https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=GB&Expert=81 (Orphanet ORPHA:81) - https://rarediseases.org/rare-diseases/antisynthetase-syndrome/ (NORD overview)

Curation handoff notes

A kb/disorders/Antisynthetase_Syndrome.yaml entry already exists on this branch (MONDO:0019344, with pathophysiology and phenotype scaffolding). This report is structured to fill it out — prioritize: (1) the verified mechanism chain from PMID 36280495 (autoantigen secretion → WHEP epitope → immune complex → TLR7/8 → IFN loop → tissue damage); (2) antibody-subtype phenotype heterogeneity (§9); (3) the ILD-centric prognosis/treatment (§§11–12). Before any snippet becomes an evidence: item, run just fetch-reference PMID:XXXX then confirm the quote is an exact substring of the cached abstract — especially for every claim I flagged [search-derived], and watch for the mechanic's-hands and Raynaud HPO terms, which need OAK verification (the ontology may lack precise matches).